European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation

Cheng-Hung Li1,2,*, Chia-Jen Liu3,4,*, Annie Y. Chou5, Tze-Fan Chao2,6, Ta-Chuan Tuan2,6, Su-Jung Chen6,7, Kang-Ling Wang2,6, Yenn-Jiang Lin2,6, Shih-Lin Chang2,6, Li-Wei Lo2,6, Yu-Feng Hu2,6, Fa-Po Chung2,6, Jo-Nan Liao2,6, Tzeng-Ji Chen8, Tsu-Juey Wu1,2 & Shih-Ann Chen2,6

This study compared the risk of mortality in atrial fibrillation (AF) patients treated adherent to the 2012 European Society of Cardiology (ESC) guidelines for stroke prevention and those who were not treated according to guideline recommendations. This study used the Taiwan National Health Insurance Research Database. From 1996 to 2011, 354,649 newly diagnosed AF patients were identified as the study population. Among the study cohort, 45,595 and 309,054 patients were defined as Guideline-Adherent and Non-Adherent groups, respectively. During the follow up of 1,480,280 person-years, 133,552 (37.7%) patients experienced mortality. The risk of mortality was lower among AF patients whose treatment was adherent to the guideline recommendation for stroke prevention than those whose treatment was not (annual risk of mortality = 4.3% versus 10.0%) with an adjusted hazard ratio of 0.62 (95% confidence interval = 0.61–0.64, p value < 0.001) after adjusting for age, gender, CHA2DS2-VASc score and antiplatelet therapy. The findings were consistently observed after propensity matching analysis. In conclusion, the risk of mortality was lower for AF patients who were treated according to the antithrombotic recommendations of the 2012 ESC guidelines, guided by the CHA2DS2-VASc score. Better efforts to implement guidelines would lead to improved outcomes for patients with AF.

Atrial fibrillation (AF) is the most common and prevalent arrhythmia in the worldwide population1,2 and is independently associated with increased mortality and serious cardiovascular events such as ischemic stroke, transient ischemic attacks (TIA), and systemic thromboembolism3,4. Patients with AF have a five-fold increased stroke risk compared to patients in sinus rhythm5,6. Stroke patients with AF are characterized by a higher mortality, a prolonged hospitalization duration and a worse functional outcome7–10.

Oral anticoagulants (OACs) significantly reduce the risk of AF-related stroke11,12 but also increase the risk of bleeding13. The absolute benefit of OACs depends on the underlying risk of stroke. A simple assessment tool, the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) risk score, is recommended and advocated in current guidelines to stratify individual stroke risk in patients with AF14,15. According to the European Society of Cardiology (ESC) guidelines, low-risk patients (defined by CHA2DS2-VASc score of 0 for males and 1 for...
females) do not require antithrombotic therapy. AF patients with ≥1 additional stroke risk factor beyond gender should be offered OACs for effective stroke prevention.

Despite the clear recommendations for stroke prevention in the guidelines, OACs are still under-used in real-world practice16–18, and adherence to treatment guidelines in AF patients is suboptimal19–23. A recent report from the EuroObservational Research Programme-Atrial Fibrillation (EORP-AF) Pilot General Registry, which enrolled 2,634 AF patients, demonstrated that ESC guideline-adherent antithrombotic management is associated with better outcomes24. However, the importance of guideline adherence for stroke prevention has not previously been well studied for Asian AF patients. The present study aimed to compare the risk of mortality in AF patients treated adherent or not adherent to the 2012 ESC guidelines for stroke prevention.

Methods

Database. The protocol of the present study is similar to our previous studies25–30. This retrospective study used the National Health Insurance Research Database (NHIRD) of the Taiwan National Health Research Institute. The National Health Insurance system is a mandatory universal program that offers comprehensive medical care coverage to all Taiwanese residents. Information in the NHIRD consists of detailed health care data from more than 23 million enrollees, representing >99% of Taiwan's population. In this cohort dataset, the patients' original identification numbers have been encrypted to protect privacy, with a consistent encrypting procedure to ensure linkage of claims belonging to the same patient and to allow patients to be followed over time. Information about important co-morbid conditions of each individual was retrieved from the medical claims based on the International Classification of Diseases-Ninth Revision-Clinical Modification codes. We defined patients with a certain disease only when it was a discharge diagnosis or confirmed more than twice in the outpatient department. The diagnostic accuracies of important co-morbidities, such as hyperlipidemia, heart failure, hypertension, myocardial infarction, diabetes mellitus, and chronic obstructive pulmonary disease, have been validated previously31,32. Information about the medications the patients used was retrieved from the NHIRD using the specific code of each drug registered by physicians responsible for the treatment of the patients for the purpose of getting reimbursement from the National Health Insurance system. All anti-thrombotic drugs, including warfarin and aspirin, should be prescribed by physicians, and were not available over the counter in Taiwan.

Study cohort. From January 1, 1996, to December 31, 2011, a total of 354,649 AF patients aged 20 years or older were identified from the NHIRD as the study population. AF was diagnosed using the International Classification of Diseases-Ninth Revision-Clinical Modification code (427.31) registered by the physicians responsible for treatment. To ensure diagnostic accuracy, we defined patients with AF when it was a discharge diagnosis or confirmed more than twice in the outpatient department33. The diagnostic accuracy of AF using the definition in the NHIRD was previously validated34,35. The CHA2DS2-VASc risk score was calculated for each patient by assigning 1 point each for age between 65–74 years; history of hypertension, diabetes mellitus, recent heart failure, and/or vascular disease (myocardial infarction or peripheral artery disease); and female sex. Two points each were assigned for a history of stroke, TIA, or age 75 years or older36.

Definition of guideline adherence. Guideline adherence was based on compliance with anti-thrombotic recommendations for AF stroke prevention according to the CHA2DS2-VASc score. According to the 2012 ESC AF guidelines, Guideline-adherent was defined as the following: (1) For AF males with a CHA2DS2-VASc score of 0 and AF females with a score of 1 (for gender), no anti-thrombotic drug was necessary, (2) For AF patients with an additional risk factor of the CHA2DS2-VASc scheme in addition to gender, an OAC should be prescribed. Patients who received treatment different from these recommendations were defined as “Non-adherent”. The clinical endpoint was defined as all-cause mortality.

Propensity match analysis. We performed propensity score–matched analyses for patients adherent or non-adherent to ESC guideline. We calculated propensity scores for the likelihoods of adherence to guideline compared to non-adherence by multivariate logistic regression analyses, conditional on all baseline covariates listed in Table 1. After that, we matched patients who were adherent or non-adherent to ESC guideline with a 1:1 ratio on the basis of age, sex and the closest propensity score for the guideline adherence within a threshold of ±0.00001.

Statistical analysis. Data were presented as the mean ± standard deviation (SD) for continuous variables and proportions for categorical variables. An unpaired 2-tailed Student t test was used for the analysis of continuous variables, and the differences between nominal variables were compared by the chi-square test. The incidence rate of all-cause mortality was calculated by dividing the number of events by person-time at risk with the 95% confidence interval (CI) estimated by using Fisher's exact test. The risk of all-cause mortality was assessed using Cox regression analysis. Statistical significance was set at p < 0.05, and all statistical analyses were carried out with SPSS 17.0 (SPSSC, Chicago, Illinois).

Results

Figure 1 shows the flowchart of patient enrollment. Among 354,649 AF patients ≥20 years old, 45,595 and 309,054 patients belong to the Guideline-adherent and Non-adherent groups, respectively. The percentage of guideline adherence stratified by CHA2DS2-VASc score is shown in Fig. 2. The guideline-adherent rate was lower for patients with a high CHA2DS2-VASc score.

Table 1 shows the baseline characteristics of patients in each group. Guideline-adherent patients were younger, had fewer comorbidities, and had a lower CHA2DS2-VASc score compared to Non-adherent patients. A total of 43.8% of patients in the ESC guideline Non-adherent group received anti-platelet agents for stroke prevention.
Table 1. Baseline characteristics of study patients. AF = atrial fibrillation; ESRD = end-stage renal disease; IQR = interquartile range; TIA = transient ischemic attack.

| Variables                        | Guideline-adherent (n = 45,595) | Non-adherent (n = 309,054) | P value |
|----------------------------------|---------------------------------|---------------------------|---------|
| Age, years                       | 61.0 ± 15.5                     | 72.9 ± 11.9               | < 0.001 |
| Age > 65, n (%)                  | 19,665 (43.1)                   | 244,176 (79.0)            | < 0.001 |
| Age > 75, n (%)                  | 9,972 (21.9)                    | 155,066 (50.2)            | < 0.001 |
| Male gender, n (%)               | 25,553 (56.0)                   | 170,918 (55.3)            | 0.003   |
| Comorbidities, n (%)             |                                 |                           |         |
| Congestive heart failure         | 14,615 (32.1)                   | 130,355 (42.2)            | < 0.001 |
| Hypertension                     | 20,607 (45.2)                   | 222,215 (71.9)            | < 0.001 |
| Diabetes mellitus                | 8,005 (17.6)                    | 93,369 (30.2)             | < 0.001 |
| Previous stroke/TIA              | 13,204 (29.0)                   | 110,465 (35.7)            | < 0.001 |
| Vascular disease                 | 7,479 (16.4)                    | 72,888 (23.6)             | < 0.001 |
| Hyperlipidemia                   | 9,114 (20.0)                    | 79,478 (25.7)             | < 0.001 |
| Chronic lung disease             | 10,101 (22.2)                   | 115,792 (37.5)            | < 0.001 |
| Liver cirrhosis                  | 1,212 (2.7)                     | 10,663 (3.5)              | < 0.001 |
| ESRD                             | 368 (0.8)                       | 7,478 (2.4)               | < 0.001 |
| Malignancy                       | 2,013 (4.4)                     | 17,527 (5.7)              | < 0.001 |
| CHA2DS2-VASc score, median (IQR) | 2 (1–5)                         | 4 (3–6)                   | < 0.001 |
| Use of anti-platelet agents, n (%)| 0 (0)                           | 135,488 (43.8)            | < 0.001 |

Figure 1. From 1996 to 2011, 354,649 AF patients older than 20 years old were identified from Taiwan’s NHIRD as the study population. Among the study population, 45,595 and 309,054 patients were defined as Guideline-adherent and Non-adherent groups, respectively. The risk of mortality was analyzed and compared between these two groups. AF = atrial fibrillation; CHA2DS2-VASc = congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female; ESC = European Society of Cardiology; NHIRD = National Health Insurance Research Database.
During the follow up of 1,480,280 person-years, the primary endpoint of mortality occurred in 133,552 (37.7%) patients. The risk of mortality was lower in Guideline-adherent AF patients than in Non-adherent AF patients (annual risk of mortality $= 4.3\%$ versus 10.0%), (Table 2). The cumulative mortality incidence curves of the two groups are shown in Fig. 3.

Table 3 shows the risk of mortality for patients who received treatment adherent to the ESC guidelines compared to those who did not. ESC guideline-adherent antithrombotic strategy was associated with a lower risk of mortality with an adjusted hazard ratio (HR) of $0.62$ (95% CI $= 0.61–0.64$, p value $< 0.001$) after adjusting for age, gender, CHA2DS2-VASc score, baseline differences and the use of antiplatelet therapy (Table 3).

The baseline characteristics of patients in each group after propensity matching were shown in Supplemental Table 1. The propensity scores of 2 groups were similar. Age, sex and comorbidities were not significantly different between 2 groups. Similar to the results derived from the non-matched cohort, the annual risk of mortality was
lower among patients who were adherent compared to the non-adherent group (4.9%/year versus 6.0%/year) with an adjusted HR of 0.80 (95% CI = 0.78–0.83, p value < 0.001) (Supplemental Tables 2 and 3).

Discussion

To date, the present study is the largest retrospective analysis of mortality in AF patients based on whether their treatment was adherent or not adherent to the 2012 ESC guidelines for stroke prevention. The main finding of our study is that guideline-adherent antithrombotic management was associated with a 38% lower risk of mortality. Moreover, the overall guideline adherence rate was only 13% and even lower among patients with a high CHA2DS2-VASc score in this non-selected nationwide AF registry. These observations emphasize the importance of guideline adherence since it was associated with a better survival for AF patients.

The guideline adherence rate (13%) we observed in the present study is lower than in other observational studies, which have a cumulative report an adherence rate between 53–79% and a non-adherence rate of 21–47%5,6,21–23. One possible explanation for the differences is that previous guidelines used the CHADS2 score, rather than CHA2DS2-VASc, to stratify stroke risk, and treatment decisions were focused on identifying ‘high risk’ patients who should receive OACs. In contrast, the 2012 ESC AF guidelines adopted a more sensitive CHA2DS2-VASc score for stroke risk stratification and treatment focused on initial identification of ‘low risk’ patients who did not need antithrombotic therapy, and subsequently identified all others as patients for whom an OAC should be offered. Since more patients would be recommended to receive OACs when stratified by the CHA2DS2-VASc score as per the ESC 2012 guidelines, it may further widen the gap between guideline recommendations and the daily practices of the real world. Another plausible explanation could be that Asian patients are at a higher risk of warfarin-related intracranial hemorrhage (ICH) than other ethnicities39, and the concern of ICH may result in lower guideline adherence in Asia.

Several previous studies have investigated the impact of guideline adherence on the clinical outcomes of systemic thromboembolism (TE) and bleeding23,37. However, these previous studies focused on the 2001 and 2006 AF guidelines which adopted CHADS2 score for stroke risk stratification23,37, and data about the risk of mortality and adherence to CHA2DS2-VASc-based guidelines are limited. Recently, Lip et al. reported from the EORP-AF Pilot General Registry43 that event rates for any TE, the composite endpoints of all-cause mortality & any TE and ‘cardiovascular death, any TE or bleeding’ were significantly lower in guideline-adherent patients. However, ‘any cause of death’ alone was non-significant (p = 0.0777), which may have been due to the relatively short follow-up duration and the small number of deaths. In the present study, which enrolled a large number of AF subjects followed for more than 1,480,000 person-years, the risk of mortality was 22% lower for patients whose treatment was adherent to the 2012 ESC AF guidelines for stroke prevention compared to those whose treatment was not.

In the meta-analysis performed by Hart et al., the use of warfarin not only reduced the risk of stroke by 64%, it also reduced the risk of all-cause mortality by about 25%40. Our study findings reinforce that guideline adherence can improve patient survival.

Older age and multiple comorbidities likely move physicians to discard OAC use precluding compliance with guideline recommendations. Similar to other observational studies41–44, our data showed that patients who were not treated according to guidelines were older, and have more comorbidities and a higher CHA2DS2-VASc score. A common argument to withhold OAC use in the elderly is the risk of major bleeding, particularly ICH. Certain patients with multiple comorbidities have a higher HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) score, and an increased risk of major bleeding with OAC use45. However, the decision on use of OACs should be based on the stroke risk as assessed by the CHA2DS2-VASc score, reserving the HAS-BLED score to assist clinicians in identifying correctable risk factors for bleeding45. Supportively, a previous study demonstrated that patients were willing to endure 4.4 major bleeds in order to prevent one stroke46. Therefore, management of patients with a high risk for both ischemic stroke and bleeding should be based on joint and informed decision-making with patients, rather than based on the decision of physicians alone.

Study limitations. This study was an observational study and has several limitations. First, patients were categorized into guideline-adherent or non-adherent groups according to the baseline antithrombotic treatments the patients received. The strategies for AF stroke prevention could be changed during the follow-up. We could not ascertain the drug adherence and the reason for non-adherence during the follow-up. However, at the timing when patients experienced mortality or at the end of follow up, more than 80% of patients were still categorized as the same groups as they were at the baseline. Furthermore, since patients who did not receive antithrombotic agents at enrollment were allowed to take OACs during follow-up according to the guideline recommendation and were not excluded from the analysis, the true risk of mortality for patients in the Non-adherent group could be even higher than what we reported here. Therefore, the true difference in mortality risk between these 2 groups

| Groups             | Crude HR (95% CI) | P value | Adjusted1 HR (95% CI) | P value | Adjusted2 HR (95% CI) | P value |
|--------------------|------------------|---------|----------------------|---------|----------------------|---------|
| Non-adherent       | reference        |         | reference            |         | reference            |         |
| Guideline-adherent | 0.48 (0.47–0.49) | <0.001  | 0.76 (0.75–0.78)     | <0.001  | 0.62 (0.61–0.64)     | <0.001  |

Table 3. Hazard ratio for mortality in patients treated adherent or non-adherent to the ESC guidelines for stroke prevention. HR, hazard ratio; CI, confidence interval, ESRD, end-stage renal disease. 1Adjusted for age, gender, and CHA2DS2-VASc score. 2Adjusted for age, gender, CHA2DS2-VASc score, hyperlipidemia, chronic lung disease, liver cirrhosis, ESRD, malignancy, and the use of anti-platelet agents.
could potentially be even larger. Second, the baseline characteristics were different between the 2 groups, and therefore we were not able to exclude the possibility that Non-adherent patients were older and sicker, which may have led to the observed increase in mortality. We adjusted for these potential confounders using multivariate Cox regression and propensity matching analyses. Third, we were not able to calculate the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) score for each patient because details on the amount of alcohol intake and biochemical indices of renal/liver function were not available in this registry database. The concern of severe bleeding for patients with a high HAS-BLED score may prohibit physicians from prescribing OACs, and a further study is necessary to explore the reasons why OACs were not used. Lastly, the present study only Taiwanese patients, and the suitability of result extrapolation to other populations remains uncertain.

Conclusions

In this nationwide AF cohort, the risk of mortality was lower for patients who were treated according to antithrombotic recommendations of the 2012 ESC guidelines guided by the CHA_2DS_2-VASc score. Better efforts to implement guidelines would lead to improved outcomes for patients with AF.

References

1. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Atrial fibrillation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285, 2370–2375 (2001).
2. Kozlowski, D. et al. Lone atrial fibrillation: what do we know? Heart 96, 498–503 (2010).
3. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983–988 (1991).
4. Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113, 359–364 (2002).
5. Wolf, P. A., Kannel, W. B., McGee, D. L., Meks, S. L., Bharucha, N. E. & McNamara, P. M. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 14, 664–667 (1983).
6. Sharif, N. et al. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med 126, 887–893 (2013).
7. Dulli, D. A., Stanko, H. & Levine, R. L. Atrial fibrillation is associated with severe acute ischemic stroke. Neuropediatrics 22, 118–123 (2003).
8. Marini, C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36, 1115–1119 (2005).
9. Thomson, R., Parkin, D., Eccles, M., Sudlow, M. & Robinson, A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 355, 956–962 (2000).
10. Carlsson, J. et al. Neurological events in patients with atrial fibrillation: outcome and preventive practices. Z Kardiol 89, 1090–1097 (2000).
11. Hart, R., Benavente, O., McBride, R. & Perace, L. A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131, 492–501 (1999).
12. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154, 1449–1457 (1994).
13. Kozlowski, D., Budrejko, S., Raczak, G., Rysz, J. & Banach, M. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists. Curr Pharm Des 19, 3816–3826 (2013).
14. Camm, A. J. et al. ESC Committee for Practice Guideline (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Euro Heart J 33, 2719–2747 (2012).
15. January, C. T. et al. ACC/AHA Task Force Members. 2014 ACC/AHA/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, 2071–2104 (2014).
16. Walker, A. M. & Bennett, D. Epidemiology and outcomes in patients with atrial fibrillation in the Unites States. Heart Rhythm 5, 1365–1372 (2008).
17. Ogilvie, I. M., Newton, N., Welner, S. A., Cowell, W. & Lip, G. Y. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Ann Intern Med 115, 1449–1457 (1994).
18. Xiong, Q., Shantsila, A., Li, J., Hong, K. & Lip, G. Y. Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project. Arch Med Sci 12, 216–218 (2016).
19. Friberg, L., Hammar, N., Ringh, M., Pettersson, H. & Rosenqvist, M. Stroke prophylaxis in atrial fibrillation: What do we know? Heart Rhythm 11, 1339–1347 (2015).
20. Andersson, P., Londahl, M., Abdou, N. J. & Terent, A. The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: Implications for anticoagulation prophylaxis. J Intern Med 272, 170–176 (2012).
21. Bjorck, S., Palaszewski, B., Friberg, L. & Bergfeldt, L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke 44, 3103–3108 (2013).
22. Friberg, L. & Bergfeldt, L. Atrial fibrillation prevalence revisited. J Intern Med 274, 461–468 (2013).
23. Nieuwlaat, R. et al. Euro Heart Survey Investigators. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am J Cardiol 113, 1006–1012 (2007).
24. Lip, G. Y. et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AP General Pilot Registry. Europace 17, 1777–1786 (2015).
25. Chao, T. F. et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA_2DS_2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 11, 1941–1947 (2014).
26. Chao, T. F. et al. Using the CHA_2DS_2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 64, 1668–1663 (2014).
27. Chao, T. F. et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA_2DS_2-VASc score (beside sex) receive oral anticoagulation? J Am Coll Cardiol 65, 635–642 (2015).
28. Chao, T. F. et al. Comparisons of CHA_2DS_2 and CHA_2DS_2-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asian patients? Heart Rhythm 13, 46–53 (2016).
29. Chao, T. F. et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 66, 1339–1347 (2015).
30. Chao, T. F. et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 132, 1604–1612 (2015).
31. Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C. & Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 104, 157–163 (2005).
32. Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H. & Lai, M. L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiol Drug Saf* **20**, 236–242 (2011).
33. Chen, S. J. et al. Dental scaling and atrial fibrillation: a nationwide cohort study. *Int J Cardiol* **168**, 2300–2303 (2013).
34. Lin, I. J., Cheng, M. H., Lee, C. H., Wung, D. C., Cheng, C. L. & Kao Yang, Y. H. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation: a nationwide descriptive study in Taiwan. *Clin Ther* **30**, 1726–1736 (2008).
35. Chang, C. H. et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. *Atherosclerosis* **232**, 224–230 (2014).
36. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* **137**, 263–272 (2010).
37. Gorin, L., Fauchier, L., Nonin, E., Charbonnier, B., Babuty, D. & Lip, G. Y. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter. *Chest* **140**, 911–917 (2011).
38. Brandes, A. et al. Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: A Danish Survey. *Clin Cardiol* **36**, 427–432 (2013).
39. Shen, A. Y., Yao, J. F., Brar, S. S., Jorgensen, M. B. & Chen, W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with Atrial Fibrillation. *J Am Coll Cardiol* **50**, 309–315 (2007).
40. Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. *Ann Intern Med* **146**, 857–867 (2007).
41. Gallagher, A. M., Rietbrock, S., Plumb, J. & van Staa, T. P. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? *J Thromb Haemost* **6**, 1500–1506 (2008).
42. The FALSTAF study group. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. *Pharmacoepidemiol Drug Saf* **16**, 32–38 (2007).
43. Ruigomez, A., Johansson, S., Wallander, M. A. & Rodriguez, L. A. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. *J Clin Epidemiol* **55**, 358–363 (2002).
44. DeWilde, S., Carey, I. M., Emms, C., Richards, N. & Cook, D. G. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. *Heart* **92**, 1064–1070 (2006).
45. Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. & Lip, G. Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* **138**, 1093–1100 (2010).
46. Lahaye, S., Regpala, S., Lacombe, S., Sharma, M., Gibbens, S., Ball, D. & Francis, K. Evaluation of patients’ attitude towards stroke prevention and bleeding risk in atrial fibrillation. *Thromb Haemost* **111**, 465–473 (2014).

**Acknowledgements**
This work was supported in part by grants from the National Science Council (MOST 104-2314-B-075-024-MY3), and Taichung Veterans General Hospital (TCVGH-1053103B, TCVGH-1053105C).

**Author Contributions**
The specific contributions made to this article by the listed authors are as follows: C.-H.L. drafted the manuscript. C.-J.L., S.-J.C., T.-C.T., K.-L.W. and T.-J.C. plotted the figures. Y.-J.L., S.-L.C., L.-W.L., Y.-F.H., F.-P.C. and J.-N.L. collected the data and C.-J.L. performed data analysis. C.-H.L., C.-J.L., T.-F.C., T.-J.W. and S.-A.C. designed the study. A.-Y.C., T.-F.C. and S.-A.C. revised the manuscript and took responsibility for the interpretation of the results. All authors have reviewed the manuscript.

**Additional Information**
Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Li, C.-H. et al. European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation. *Sci. Rep.* **6**, 30734; doi: 10.1038/srep30734 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016